Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.21

€1.21

0.500%
0.006
0.500%
€3.76
 
18:14 / Tradegate WKN: A14SSK / Symbol: LXRX / Name: Lexicon PHARM / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Lexicon Pharmaceuticals Inc. Stock

The Lexicon Pharmaceuticals Inc. stock is trending slightly upwards today, with an increase of €0.006 (0.500%) compared to yesterday's price.
Currently there is a rather positive sentiment for Lexicon Pharmaceuticals Inc. with 6 Buy predictions and 3 Sell predictions.
Based on the current price of 1.21 € the target price of 3 € shows a potential of 147.32% for Lexicon Pharmaceuticals Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Lexicon Pharmaceuticals Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Lexicon Pharmaceuticals Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Lexicon Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Lexicon Pharmaceuticals Inc. 0.500% -1.858% 12.813% 81.073% 64.189% -40.746% -14.707%
Ardelyx Inc. -1.090% 1.501% 6.242% -4.991% 3.525% 200.937% -1.306%
Krystal Biotech 1.290% 6.399% 17.592% 14.742% 32.194% 183.380% -
Evolus Inc -1.720% -2.521% -4.132% -50.847% -44.762% -12.782% 90.164%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-28

Betrachtet man die Finanzdaten der Lexicon Pharmaceuticals, kann man sehen, dass das Unternehmen in einer komplexen finanziellen Situation steckt, die für Biotechnologie- und medizinische Forschungsunternehmen typisch ist. Da die meisten Unternehmen in dieser Branche sich auf Forschung und Entwicklung konzentrieren, sind hohe Kosten und Umsätze oft sehr variabel. Es scheint jedoch, dass Lexicon PHARM einige Herausforderungen zu bewältigen hat, wie die Analyse der bereitgestellten Finanzdaten zeigt.

Erstens ist das Unternehmen nachhaltig investiert, wie die hohen Beträge für Forschung und Entwicklung (R&D) zeigen. Investitionen in die Forschung sind für Unternehmen in der Biotechnologie und medizinischen Forschung von entscheidender Bedeutung, um innovative Produkte und Therapien zu entwickeln, die letztlich zu hohen Gewinnen führen können.

Zweitens hat Lexicon PHARM eine solide Bilanz mit erheblichen Beträgen an Vermögenswerten. Diese Vermögenswerte könnten das Unternehmen vor finanziellen Schwierigkeiten schützen und es könnte sie zur Finanzierung seiner fortlaufenden Forschungs- und Entwicklungsbemühungen nutzen.

Comments

Prediction Buy
Perf. (%) 26.55%
Target price 3.418
Change
Ends at 02.09.26

Lexicon Pharmaceuticals (NASDAQ:LXRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for LXRX provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 91.78%
Target price 3.451
Change
Ends at 24.06.26

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for LXRX provided by MarketBeat
Show more

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for LXRX provided by MarketBeat
Show more